SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Albany Molecular Research, Inc. (AMRI)

NEW YORK, July 13, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims of whether the board members of Albany Molecular Research, Inc. ("AMRI" or the "Company") (NASDAQ: AMRI) breached their fiduciary duties in connection with the proposed sale of the Company to The Carlyle Group and GTCR LLC. Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/amri.

On June 6, 2017 AMRI announced that it has signed a definitive agreement to be acquired by affiliates of The Carlyle Group and GTCR LLC. Under the terms of the agreement, AMRI shareholders will receive $21.75 in cash for each share of AMRI.

The investigation focuses on whether the AMRI board members failed to fulfill their duties to the shareholders and whether The Carlyle Group and GTCR LLC is underpaying for AMRI.

If you are a shareholder of AMRI and would like to learn more about this investigation you can visit the firm's site: www.bgandg.com/amri. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]

SOURCE Bronstein, Gewirtz & Grossman, LLC

Related Links

http://www.bgandg.com